Thursday, April 25, 2024 4/25/2024

Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment Response

Award Number: R01AI146917
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Hepatitis delta virus (HDV) is an infectious subviral agent that can propagate in individuals infected with hepatitis B virus (HBV). It is the most severe form of chronic viral hepatitis in humans and ~20 million people worldwide are estimated to be chronically infected. In the U.S., the prevalence of chronic HDV infection is rising with recent data suggesting an urgent need for screening and treatment. There is no FDA approved treatment for HDV with current therapy consisting of pegylated interferon-alpha which only achieves cure in ~25% of patients. With limited treatment data available, understanding the dynamics of HDV infection and treatment response is in its infancy. The new prenylation inhibitor lonafarnib is the first direct acting anti-HDV agent being tested clinically, but pegylated interferon-lambda, Nucleic acid polymers and HDV/HBV entry inhibitor myrcludex B are also being investigated as anti-HDV therapies providing ongoing opportunities characterize HDV treatment dynamics and the mechanism of action of HDV antivirals and provide a window into the dynamics among HDV, HBV and host during co-infection. To gain insights into HDV-HBV-host-drug dynamics we have established an interdisciplinary team that includes clinicians who perform HDV treatment clinical trials, experimentalists to perform treatment and HDV/HBV coinfection studies in humanized mouse models and mathematical modelers to create mathematical/computational models to explain the patient and mouse data. The long-term goal of this proposal is to determine the MOA of anti-HDV drugs and optimal use of antiviral agents for the treatment of HDV.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $630,648 )
2024	2024	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	5	1/17/2024	NON-COMPETING CONTINUATION	$630,648
														Subtotal = $630,648

Issue Date FY: 2023 ( Subtotal = $700,720 )
2023	2023	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	4	1/31/2023	NON-COMPETING CONTINUATION	$700,720
														Subtotal = $700,720

Issue Date FY: 2022 ( Subtotal = $700,720 )
2022	2022	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	3	1/14/2022	NON-COMPETING CONTINUATION	$700,720
														Subtotal = $700,720

Issue Date FY: 2021 ( Subtotal = $700,217 )
2021	2021	LOYOLA UNIVERSITY OF CHICAGO	2160 S FIRST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	2	1/7/2021	NON-COMPETING CONTINUATION	$700,217
														Subtotal = $700,217

Issue Date FY: 2020 ( Subtotal = $725,051 )
2020	2020	LOYOLA UNIVERSITY OF CHICAGO	2160 S FIRST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	1	2/13/2020	NEW	$725,051
														Subtotal = $725,051

Grand Total All Awards = $3,457,356

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment Response

Award Number: R01AI146917

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer